文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

整合酶抑制剂耐药突变用于传播性HIV-1耐药监测的标准化列表

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are expected to be widely adopted globally, requiring surveillance of resistance emergence and transmission.…

要点

  • 24个非多态性INSTI选择突变可用于量化传播性INSTI耐药。
  • 候选列表包括T66A/I/K、E92G/Q、G118R、F121Y等24个突变。
  • 该列表需随非B亚型及度鲁特韦治疗者序列增多而更新。

核心结论

  • 一套包含24个非多态性INSTI选择突变的列表可能有助于量化INSTI相关的传播性耐药。

研究设计与样本

  • 利用17302例INSTI未治疗者和2450例INSTI治疗者的整合酶序列,根据专家列表、保守性、频率和体外敏感性贡献对突变分类。
  • 53.3%的INSTI未治疗序列和20.0%的INSTI治疗序列来自非B亚型。
  • 约10%的序列来自接受度鲁特韦单药或第一代INSTI后换用度鲁特韦者。

主要发现

  • 29个相对常见的INSTI选择突变中,24个成为INSTI监测耐药突变列表的候选。

关键数值与推荐

  • 24个候选突变为:T66A/I/K、E92G/Q、G118R、F121Y、E138A/K/T、G140A/C/S、Y143C/H/R/S、S147G、Q148H/R/K、N155H、S230R和R263K。

临床怎么用

  • 可将24个非多态性INSTI选择突变用于传播性INSTI耐药的监测和量化。

局限性

  • 列表可能需随非B亚型及接受度鲁特韦治疗者的更多序列出现而更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are expected to be widely adopted globally, requiring surveillance of resistance emergence and transmission. OBJECTIVES: We therefore sought to develop a standardized list of INSTI-resistance mutations suitable for the surveillance of transmitted INSTI resistance. METHODS: To characterize the suitability of the INSTI-resistance mutations for transmitted HIV-1 drug resistance (TDR) surveillance, we classified them according to their presence on published expert lists, conservation in INSTI-naive persons, frequency in INSTI-treated persons and contribution to reduced in vitro susceptibility. Mutation prevalences were determined using integrase sequences from 17302 INSTI-naive and 2450 INSTI-treated persons; 53.3% of the INSTI-naive sequences and 20.0% of INSTI-treated sequences were from non-B subtypes. Approximately 10% of sequences were from persons who received dolutegravir alone or a first-generation INSTI followed by dolutegravir. RESULTS: Fifty-nine previously recognized (or established) INSTI-resistance mutations were present on one or more of four published expert lists. They were classified into three main non-overlapping groups: 29 relatively common non-polymorphic mutations, occurring in five or more individuals and significantly selected by INSTI treatment; 8 polymorphic mutations; and 22 rare mutations. Among the 29 relatively common INSTI-selected mutations, 24 emerged as candidates for inclusion on a list of INSTI surveillance drug-resistance mutations: T66A/I/K, E92G/Q, G118R, F121Y, E138A/K/T, G140A/C/S, Y143C/H/R/S, S147G, Q148H/R/K, N155H, S230R and R263K. CONCLUSIONS: A set of 24 non-polymorphic INSTI-selected mutations is likely to be useful for quantifying INSTI-associated TDR. This list may require updating as more sequences become available from INSTI-experienced persons infected with HIV-1 non-subtype B viruses and/or receiving dolutegravir.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Tzou PL, Rhee SY, Descamps D, et al. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. J Antimicrob Chemother. 2020. PMID: 31617907. doi:10.1093/jac/dkz417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。